Inactivation of cellular enzymes by carbonyls and protein-bound glycation/glycoxidation products.
Diabetic plasma contains elevated levels of glucose and various low-molecular-weight carbonyl compounds derived from the metabolism of glucose and related materials. These compounds react with protein side chains (Arg, Lys, Cys, and His) to give glycated materials and advanced glycation end products. In this study, we have examined the effect of glucose and carbonyl compounds (methylglyoxal, glyoxal, glycolaldehyde, and hydroxyacetone), and glycation products arising from reaction of these materials with model proteins, on the activity of three key cellular enzymes: glyceraldehyde-3-phosphate dehydrogenase (GAPDH), glutathione reductase, and lactate dehydrogenase, both in isolation and in cell lysates. In contrast to glucose (1M, both fresh and aged for 8 weeks), which had no effect, marked inhibition of all three enzymes was observed with methylglyoxal and glyoxal. GAPDH was also inhibited by glycolaldehyde and hydroxyacetone. Incubation of these enzymes with proteins that had been preglycated with methylglyoxal, but not glucose, also resulted in significant time- and concentration-dependent inhibition with both isolated enzymes and cell lysates. This inhibition was not metal ion, oxygen, superoxide dismutase, or catalase dependent, suggesting that inhibition is not radical mediated. These effects are suggested to be due to direct adduction of the free- or protein-bound carbonyls with the target enzyme. Such an interpretation is supported by the detection of the loss of thiol groups on GAPDH and the detection of cross-linked materials on protein gels. Though direct comparison of the extent of inhibition induced by free versus protein-bound carbonyls was not possible, the significantly higher concentrations of the latter materials over the former in diabetic plasma and cells lead us to suggest that alterations in the activity of key cellular enzymes induced by glycated proteins may play a significant role in the development of diabetic complications.
The Heart Research Institute, 145 Missenden Road, Camperdown NSW 2050, Australia.
Philip E
PE
Morgan
Roger T
RT
Dean
Michael J
MJ
Davies
D000079:Acetaldehyde / Q000031:analogs & derivatives* / Q000494:pharmacology; D000096:Acetone / Q000031:analogs & derivatives* / Q000494:pharmacology; D000447:Aldehydes / Q000737:chemistry / Q000494:pharmacology*; D000818:Animals; D002478:Cells, Cultured; D004789:Enzyme Activation; D004798:Enzymes / Q000187:drug effects / Q000378:metabolism*; D005947:Glucose / Q000494:pharmacology; D005980:Glutathione Reductase / Q000187:drug effects / Q000378:metabolism; D017127:Glycation End Products, Advanced / Q000737:chemistry / Q000494:pharmacology*; D024601:Glyceraldehyde 3-Phosphate Dehydrogenase (NADP+) / Q000737:chemistry / Q000187:drug effects / Q000378:metabolism; D006037:Glyoxal / Q000494:pharmacology; D007770:L-Lactate Dehydrogenase / Q000187:drug effects / Q000378:metabolism; D051379:Mice; D008970:Molecular Weight; D011506:Proteins / Q000378:metabolism; D011765:Pyruvaldehyde / Q000494:pharmacology; D013438:Sulfhydryl Compounds
D000447:Aldehydes; D004798:Enzymes; D017127:Glycation End Products, Advanced; D011506:Proteins; D013438:Sulfhydryl Compounds; D000096:Acetone; D006037:Glyoxal; D011765:Pyruvaldehyde; C004433:acetol; D007770:L-Lactate Dehydrogenase; D024601:Glyceraldehyde 3-Phosphate Dehydrogenase (NADP+); D005980:Glutathione Reductase; D000079:Acetaldehyde; D005947:Glucose; C010972:glycolaldehyde